Experts explain who benefits from menin inhibitors in AML, which tests to order at relapse, and how to choose revumenib vs ziftomenib.
Uma Borate, MBBS
Advertisement
Articles by Uma Borate, MBBS
Experts explain how menin inhibitors target KMT2A and NPM1 AML, why retesting matters, and how to choose approved drugs or trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma
5